Across multiple therapeutic areas and every phase of development, you’ll have access to ophthalmology’s brightest minds with every study.


Have any questions? We’ve got answers.

What does Ora specialize in? Is Ora only ophthalmology?

At Ora, we take pride in our specialization in ophthalmology, and view our focus as a strength, not a limitation. Over our history, we’ve created a record of unsurpassed operational excellence, and committed ourselves to conducting the most rigorous science in our field.

The expertise and leadership we’ve developed extends to every subspecialty in ophthalmology, comfortably covering both pharma and device. Having directly assisted in over 85 product approvals, no one is better positioned to guide patients and partners through ophthalmic clinical research than we are.

Ora’s entire history and identity are centered exclusively around ophthalmology. No other company has the subject matter authority or the record of success that we do now, nor do they have the dedicated talent and resources that we can provide to every single program we work on. So long as you’re in ophthalmology, your specialty is ours, too.

Ora has the flexibility to provide whatever kind of support you need in order to succeed. Our in-house experts tailor their guidance to fit the exact requirements of your program, from regulatory strategy and CMC management to nonclinical program design, clinical protocols, and endpoint decisions. No matter where you are on the pathway of development, our team can help.

Our leadership team is composed of senior scientists and management executives who collectively average over 20 years of industry experience.

Ora’s Chief Medical Officer is a practicing ophthalmologist and internationally recognized glaucoma specialist, with extensive clinical research experience. He maintains a part-time appointment at Columbia University, staying at the forefront of the field and always remaining close to the patients research is meant to serve.

Our in-house R&D team has developed novel endpoints that are sensitive enough to both identify the quality-of-life benefits investigational therapies bring to patients and precisely measure the degree of improvement.

In additional to our clinical expertise, Ora’s preclinical team has extensive experience, which includes non-GLP safety studies, animal efficacy models across a wide range of ophthalmic diseases, state-of-the-art clinical instrumentation and surgical capabilities, as well as compound identification and ophthalmic formulation partnerships.

For over 45+ years, Ora has been on the leading edge of ophthalmic product development.

When your product shows promise, let's prove it.

Ora, Inc websites use cookies. By continuing to browse the site you are agreeing to our use of cookies.
For more details about cookies and their use, please see our Privacy Policy.